Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dubsky, PC; Jakesz, R; Mlineritsch, B; Pöstlberger, S; Samonigg, H; Kwasny, W; Tausch, C; Stöger, H; Haider, K; Fitzal, F; Singer, CF; Stierer, M; Sevelda, P; Luschin-Ebengreuth, G; Taucher, S; Rudas, M; Bartsch, R; Steger, GG; Greil, R; Filipcic, L; Gnant, M.
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2012; 30(7):722-728
Doi: 10.1200/JCO.2011.36.8993
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Luschin-Ebengreuth Gero
- Samonigg Hellmut
- Stöger Herbert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer. The ABCSG-8 (Austrian Breast and Colorectal Cancer Study Group 8) study is a large phase III clinical trial addressing the sequence strategy containing ANA in comparison with 5 years of TAM in a low- to intermediate-risk group of postmenopausal patients. Endocrine receptor-positive patients with G1 or G2 tumors were eligible. After surgery, patients were randomly assigned to 5 years of TAM or 2 years of TAM followed by 3 years of ANA. Adjuvant chemotherapy and G3 and T4 tumors were exclusion criteria. Intention-to-treat and censored analyses of on-treatment recurrence-free survival (RFS) were performed, and exploratory survival end points and toxicity were investigated. Information from 3,714 patients, including 17,563 woman-years, with a median of 60 months of follow-up was available for this analysis. Median age was 63.8 years, 75% were node negative, and 75% had T1 tumors. Sequencing of ANA after identical 2-year treatment with TAM in both arms did not result in a statistically significant improvement of RFS (hazard ratio [HR], 0.80; 95% CI, 0.63 to 1.01; P = .06). Exploratory analyses of distant relapse-free survival indicated a 22% improvement (HR, 0.78; 95% CI, 0.60 to 1.00). On-treatment adverse events and serious adverse events were consistent with known toxicity profiles of ANA and TAM treatment. Despite a low overall rate of recurrence in a population with breast cancer at limited risk of relapse, the a priori sequence strategy of 2 years of TAM followed by 3 years of ANA led to small outcome and toxicity benefits.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Aromatase Inhibitors - administration & dosage
- Aromatase Inhibitors - adverse effects
- Aromatase Inhibitors - therapeutic use
- Aromatase Inhibitors -
- Breast Neoplasms - drug therapy
- Breast Neoplasms - pathology
- Breast Neoplasms - surgery
- Disease-Free Survival -
- Drug Administration Schedule -
- Female -
- Humans -
- Middle Aged -
- Neoplasm Recurrence, Local - pathology
- Nitriles - administration & dosage
- Nitriles - adverse effects
- Nitriles - therapeutic use
- Prospective Studies -
- Survival Rate -
- Tamoxifen - administration & dosage
- Tamoxifen - adverse effects
- Tamoxifen - therapeutic use
- Triazoles - administration & dosage
- Triazoles - adverse effects
- Triazoles - therapeutic use